ZyVersa Therapeutics posts $20.7 million pre-tax loss for Q3 2025

Reuters11-20

ZyVersa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts $20.7 million pre-tax loss for Q3 2025

ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for the third quarter ended September 30, 2025, compared to a pre-tax loss of $2.4 million for the same period in 2024. The increase in losses was primarily due to an $18.6 million impairment of research and development, related to a decline in market capitalization and uncertainty around financing research milestones. Cash on hand as of September 30, 2025, was $0.5 million. ZyVersa raised approximately $2.1 million in the third quarter and $4.1 million year-to-date. The company is advancing its pipeline, including VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, and is seeking additional financing to support ongoing operations and development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579105-en) on November 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584975279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584975279","market":"fut","top_or_hot":-1,"title":"ZyVersa Therapeutics posts $20.7 million pre-tax loss for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ZyVersa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posts $20.7 million pre-tax loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for the third quarter ended September 30, 2025, compared to a pre-tax loss of $2.4 million for the same period in 2024. The increase in losses was primarily due to an $18.6 million impairment of research and development, related to a decline in market capitalization and uncertainty around financing research milestones. Cash on hand as of September 30, 2025, was $0.5 million. ZyVersa raised approximately $2.1 million in the third quarter and $4.1 million year-to-date. The company is advancing its pipeline, including VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, and is seeking additional financing to support ongoing operations and development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZVSA\">Zyversa Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579105-en) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZyVersa Therapeutics posts $20.7 million pre-tax loss for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZyVersa Therapeutics posts $20.7 million pre-tax loss for Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 05:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ZyVersa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posts $20.7 million pre-tax loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for the third quarter ended September 30, 2025, compared to a pre-tax loss of $2.4 million for the same period in 2024. The increase in losses was primarily due to an $18.6 million impairment of research and development, related to a decline in market capitalization and uncertainty around financing research milestones. Cash on hand as of September 30, 2025, was $0.5 million. ZyVersa raised approximately $2.1 million in the third quarter and $4.1 million year-to-date. The company is advancing its pipeline, including VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, and is seeking additional financing to support ongoing operations and development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZVSA\">Zyversa Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579105-en) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL1pNQjy:1","article_id":"2584975279","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584975279","pubTimestamp":1763587217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for the third quarter ended September 30, 2025, compared to a pre-tax loss of $2.4 million for the same period in 2024. The increase in losses was primarily due to an $18.6 million impairment of research and development, related to a decline in market capitalization and uncertainty around financing research milestones. Cash on hand as of September 30, 2025, was $0.5 million. ZyVersa raised approximately $2.1 million in the third quarter and $4.1 million year-to-date. The company is advancing its pipeline, including VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, and is seeking additional financing to support ongoing operations and development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","ZVSA":"ZyVersa Therapeutics, Inc.","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"ZyVersa Therapeutics公布2025年第三季度税前亏损2070万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ZVSA":0.9},"content_text":"ZyVersa Therapeutics posts $20.7 million pre-tax loss for Q3 2025\n    \n\n        ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for the third quarter ended September 30, 2025, compared to a pre-tax loss of $2.4 million for the same period in 2024. The increase in losses was primarily due to an $18.6 million impairment of research and development, related to a decline in market capitalization and uncertainty around financing research milestones. Cash on hand as of September 30, 2025, was $0.5 million. ZyVersa raised approximately $2.1 million in the third quarter and $4.1 million year-to-date. The company is advancing its pipeline, including VAR 200 for kidney diseases and IC 100 for chronic inflammatory diseases, and is seeking additional financing to support ongoing operations and development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579105-en) on November 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584975279","isCrawlerRequest":true}